BiomX Inc. announced a one-for-ten (1-for-10) reverse stock split of its common stock, effective September 9, 2026. The action was approved by stockholders on August 25, 2026, and finalized by the Board of Directors on August 28, 2026. This corporate action reduces authorized shares from 750 million to 150 million and decreases outstanding shares from approximately 26.7 million to 2.7 million. Fractional shares will be rounded up to the next whole share, and proportional adjustments apply to warrants and equity awards. BiomX Inc. operates in the biotechnology industry, focusing on developing microbiome-based therapies for inflammatory bowel disease.
More from Tessera Defense & Homeland Security Inc.
